Coherus Oncology (CHRS) Cash from Operations (2013 - 2026)
Coherus Oncology (CHRS) reported Cash from Operations of 57886000.0 for Q1 2026, down 124.14% on a YoY basis from 239808122.55 in Q1 2025, and down 193.6% sequentially from 19716000.0 in Q4 2025.
Coherus Oncology (CHRS) Cash from Operations (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Cash from Operations data on file, last reported at 57886000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 124.14% year-over-year to 57886000.0; the trailing twelve-month figure through Mar 2026 stood at 170573000.0 (down 34214.6% YoY), and the FY2025 full-year result was 138513000.0, down 577.66% from the prior year.
- Cash from Operations eased to 57886000.0 in Q1 2026, from 19716000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 59734000.0 in Q2 2024 to a low of 99953000.0 in Q4 2022.
- A 5-year average of 37226294.12 and a median of 46632000.0 in 2025 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 26515.43% in 2022 and surged 321.13% in 2024, its largest moves.
- Tracing CHRS's Cash from Operations over 5 years: stood at 99953000.0 in 2022, then soared by 87.06% to 12937000.0 in 2023, then surged by 321.13% to 28608000.0 in 2024, then sank by 168.92% to 19716000.0 in 2025, then sank by 193.6% to 57886000.0 in 2026.
- Business Quant data shows CHRS's Cash from Operations at 57886000.0 in Q1 2026, 19716000.0 in Q4 2025, and 46339000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -57.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.89 Mn |
| Mar 31, 2026 | -57.89 Mn |
| Dec 31, 2025 | -19.72 Mn |
| Dec 31, 2025 | -19.72 Mn |
| Sep 30, 2025 | -46.34 Mn |
| Sep 30, 2025 | -46.34 Mn |
| Jun 30, 2025 | -46.63 Mn |
| Jun 30, 2025 | -46.63 Mn |
| Mar 31, 2025 | -25.83 Mn |
| Mar 31, 2025 | -25.83 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Sep 30, 2024 | -62.02 Mn |
| Sep 30, 2024 | -62.02 Mn |
| Jun 30, 2024 | 59.73 Mn |
| Jun 30, 2024 | 59.73 Mn |
| Mar 31, 2024 | -46.77 Mn |
| Mar 31, 2024 | -46.77 Mn |
| Dec 31, 2023 | -12.94 Mn |
| Dec 31, 2023 | -12.94 Mn |